Targeting EET formation reduces thrombus formation. (A) C57BL6 mice, treated with anti-Siglec-F antibodies (n = 12) did not develop long-lasting, occlusive thrombi after FeCl3 application to the carotid artery. Treatment with an isotype-control (n = 11) did not impair thrombus development. (B) Representative image of thrombus formation 20 minutes after initial endothelial damage of a mouse treated with Siglec-F antibody and control mouse (thrombus area marked with white dotted line; artery walls marked with white lines; recanalization marked with dotted line). (C-D) Mice treated with anti-Siglec-F and isotype control show no differences in numbers of eosinophils in blood or in thrombi. (E) The number of eosinophils forming EETs in thrombi of mice treated with Siglec-F antibody (n = 4) decreased significantly compared with isotype control (n = 4). For panels A and C-E, data are mean ± SD. *P < .05.